DelveInsight's "Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The Multiple Myeloma market report provides current treatment practices, emerging drugs, Multiple Myeloma market share of the individual therapies, and current and forecasted Multiple Myeloma market Size from 2019 to 2032 segmented by seven major markets.
Some of the Key Facts of the Multiple Myeloma Market
-
In 2012, a total of 6,282 patients for whom a diagnosis of Multiple Myeloma was determined for the first time were hospitalized in France. There were nearly 3,234 males and 3,048 females (Dumontet et al. 2018).
-
In the United States, SEER and GLOBOCAN also reported comparable statistics. According to SEER, in 2020 an estimated 32,270 adults (17,530 men and 14,740 women) in the United States will be diagnosed with Multiple Myeloma which represents around 1.8% of all new cancer cases in the United States. The rate of new cases of myeloma was 7.0 per 100,000 men and women per year. In addition to this, it has also been projected that nearly 12,830 deaths (7,190 men and 5,640 women) from this disease will occur in the same year which represents around 2.1% of all cancer deaths in the United States.
Got queries? Click here to know more about the Multiple Myeloma Market Landscape
Multiple Myeloma Overview
According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. Multiple Myeloma is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74.
Multiple Myeloma Epidemiology Segmentation
-
Total Multiple Myeloma incident cases
-
Total Multiple Myeloma gender-specific cases
-
Total Multiple Myeloma diagnosed cases
-
Total Multiple Myeloma treated cases
-
Total Multiple Myeloma symptomatic cases
Multiple Myeloma Market Outlook
The Multiple Myeloma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Multiple Myeloma market trends by analyzing the impact of current Multiple Myeloma therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Multiple Myeloma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Multiple Myeloma market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Multiple Myeloma market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @ Multiple Myeloma Market Trends
Multiple Myeloma Key Companies
-
Bristol Myers Squibb
-
AbbVie
-
Roche
-
Cellectar Biosciences
-
Merck
-
And many others
Multiple Myeloma Therapies
-
Idecabtagene Vicleucel
-
Venetoclax
-
CLR 131
-
Keytruda (Pembrolizumab)
-
And many others
Table of Contents
-
Key Insights
-
Report Introduction
-
Executive Summary of Multiple Myeloma
-
Disease Background and Overview
-
Epidemiology and patient population
-
The United States
-
EU 5
-
Multiple Myeloma Emerging Therapies
-
Multiple Myeloma Market Outlook
-
Market Access and Reimbursement of Therapies
-
Multiple Myeloma Market Drivers
-
Multiple Myeloma Market Barriers
-
Appendix
-
Multiple Myeloma Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Click here to read more about Multiple Myeloma Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
